RBC Capital Maintains Outperform on Abbott Laboratories, Raises Price Target to $130
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh maintains an Outperform rating on Abbott Laboratories and raises the price target from $125 to $130.
October 08, 2024 | 6:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has increased its price target for Abbott Laboratories from $125 to $130 while maintaining an Outperform rating, indicating confidence in the company's future performance.
The increase in price target from $125 to $130 by RBC Capital suggests a positive outlook on Abbott Laboratories' future performance. Maintaining an Outperform rating indicates that the analyst expects the stock to perform better than the market average, which could lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100